Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives Average Recommendation of “Hold” from Analysts

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) have earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $48.00.

Several research analysts have commented on SNSE shares. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research report on Thursday, May 28th. Leerink Partners initiated coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Citigroup initiated coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price on the stock.

Insider Activity at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Millennium Management Llc bought 15,321 shares of the stock in a transaction on Friday, March 27th. The stock was bought at an average price of $26.61 per share, for a total transaction of $407,691.81. Following the completion of the purchase, the insider directly owned 142,360 shares in the company, valued at approximately $3,788,199.60. The trade was a 12.06% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 46,980 shares of company stock worth $1,341,669 and sold 48,067 shares worth $1,204,939. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SNSE. Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at approximately $4,188,000. Bank of America Corp DE grew its stake in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at approximately $22,758,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Price Performance

The company has a market cap of $18.98 million, a PE ratio of -0.10 and a beta of -0.25. Sensei Biotherapeutics has a one year low of $5.86 and a one year high of $36.76. The company’s 50-day moving average is $21.54 and its 200-day moving average is $19.04.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.